Kyprolis
What Kyprolis is used for
Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Kyprolis
- Active substance
- carfilzomib
- Disease area
- Multiple Myeloma
- Medicine group
- Antineoplastic agents
- ATC code
- L01XX45
- Marketing authorisation holder
- Amgen Europe B.V.
- Authorised in the EU since
- 2015
Official information
In the USA
Same active substance: Kyprolis
In India
- Carfilzomib: 3 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kyprolis used for?
Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
What is the active substance in Kyprolis?
Kyprolis contains carfilzomib.
Who makes Kyprolis?
The EU marketing authorisation holder is Amgen Europe B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU